Proteus is a provider of personalized healthcare products and services. It is commercializing a new category of therapy: Digital Medicines.

Proteus focuses on developing products, services, and data systems based on integrating medicines with ingestible, wearable, mobile, and cloud computing.

Proteus Digital Health was founded in 2004 by Andrew Thompson, George Savage & Mark Zdeblick. The company was formerly known as Proteus Biomedical, Inc. and changed its name to Proteus Digital Health, Inc. in July 2012. Proteus is headquartered in Redwood City, California with an additional office in Hayward, CA.

Proteus offerings include widely used drugs, formulated so they communicate when they have been swallowed; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers.

Proteus engages in developing and commercializing digital health products in the United States. It develops digital health products that collect and aggregate various behavioral, physiologic, and therapeutic metrics, such as medication adherence, heart rate, sleep patterns, physical activity, and stress levels—into personal management tools delivered to the mobile devices of consumers.

Proteus is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicine includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. 

Proteus is backed by Yuan Capital, Asset Management Ventures (AMV), Oracle, Novartis and many others. The company has also made a $8.8M investment in Vium on Oct 29, 2014.

Proteus was valued at $1.1B during their "Series H" funding of a $110M in Feb 26, 2016.